Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Isofol in connection with capital procurement
Mandate

Vinge advises Isofol in connection with capital procurement

June 14, 2021 Capital Markets and Public M&A

Vinge has advised Isofol Medical AB (publ), Nasdaq First North Premier Growth Market, in connection with a fully guaranteed rights issue and exercised over-allotment option which together add SEK 500 million to Isofol before transaction costs.

Vinge’s team primarily consisted of Anders Strid, Edin Agic, Jenny Sandlund and Beatrice Randow.

Related

Vinge advises Dignitana on the public offer from Paxman

 Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025

Vinge has advised Boliden in connection with a directed share issue of SEK 3.75 billion

 Vinge has advised Boliden AB in connection with a directed share issue through which the company raises proceeds of approximately SEK 3.75 billion before transaction costs.
March 21, 2025

Vinge advises EQT on its EUR 890 million sale of Dellner Couplers to Wabtec

 Vinge together with Milbank advises the EQT VIII fund (“EQT”) on its sale of Dellner Couplers (“Dellner”), a leading provider of train connection systems for passenger rail, to Wabtec Corporation (a fortune 500 company listed on the New York Stock Exchange, NYSE: WAB). The transaction values Dellner at approximately EUR 890 million. The transaction is subject to customary conditions and regulatory approvals.
March 19, 2025